Compare CAN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAN | FLGT |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.0M | 511.2M |
| IPO Year | 2019 | 2016 |
| Metric | CAN | FLGT |
|---|---|---|
| Price | $0.42 | $15.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.21 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 9.1M | 735.8K |
| Earning Date | 05-19-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | $63.64 | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $13.46 |
| 52 Week High | $2.22 | $31.04 |
| Indicator | CAN | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 39.64 |
| Support Level | $0.43 | $13.46 |
| Resistance Level | $0.55 | $22.48 |
| Average True Range (ATR) | 0.03 | 0.57 |
| MACD | -0.00 | 0.44 |
| Stochastic Oscillator | 25.79 | 65.50 |
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.